Nippon BioPharma Co., Ltd. (NBP), a major Japanese biopharmaceutical company, has established the Edo Medical Research Center (EMRC) to re-analyze the herbal and mineral compounds documented in Edo-period medical and pharmacological texts using modern science. Three drug candidates identified from primary Edo-era materials obtained through collaboration with the ancient coin research community have been announced to enter Phase I clinical trials, drawing industry attention as an innovative cross-sector cultural asset utilization model.